4214-67-9

Basic information

• Product Name: 5-Bromo-N-ethylpyrimidin-2-amine
• Synonyms: 5-Bromo-2-ethylaminopyrimidine;5-Bromo-N-ethylpyrimidin-2-amine
• CAS NO: 4214-67-9
• Molecular Formula: C₆H₈BrN₃
• Molecular Weight: 202.05182
• Mol File: 4214-67-9.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Bromo-N-ethylpyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-N-ethylpyrimidin-2-amine(4214-67-9)
• EPA Substance Registry System: 5-Bromo-N-ethylpyrimidin-2-amine(4214-67-9)

Safety Data

• Hazardous Substances Data: 4214-67-9(Hazardous Substances Data)

Usage

Description

5-Bromo-N-ethylpyrimidin-2-amine is a pyrimidine derivative with the molecular formula C7H9BrN4. It features a bromine atom attached to the fifth carbon and an ethyl group attached to the nitrogen atom. This chemical compound is widely recognized for its potential medicinal properties and is frequently utilized as an intermediate in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
5-Bromo-N-ethylpyrimidin-2-amine is used as a chemical intermediate for the synthesis of pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs, contributing to drug discovery and research processes.
Used in Agrochemical Production:
5-Bromo-N-ethylpyrimidin-2-amine is also utilized in the production of agrochemicals, where it can serve as an intermediate in the synthesis of various agricultural chemicals. Its application in this industry helps in the development of products that can improve crop yields and protect plants from pests and diseases.
Used in Specialty Chemicals:
5-Bromo-N-ethylpyrimidin-2-amine finds application in the production of specialty chemicals, where its unique properties can be harnessed for specific industrial uses. Its versatility in chemical reactions makes it a valuable component in the creation of tailored chemical products.
It is crucial to handle 5-Bromo-N-ethylpyrimidin-2-amine with care due to its potential health and environmental hazards if not used properly. Proper safety measures and guidelines should be followed to mitigate any risks associated with its use.

Upstream product

• 75-04-7 ethylamine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 1257628-59-3 3-(2-(2-(ethylamino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 1581701-21-4 C₈H₁₁N₃O₂ 
• 946706-58-7 2-(ethylamino)pyrimidine-5-carboxylic acid 
• 1581701-27-0 2-(ethylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide 
• 1360551-37-6 2-[4-(3-{1-cyclopropyl-1-[4-(2-ethylamino-pyrimidin-5-yl)-phenyl]-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide 
• 1407999-89-6 C₂₉H₃₂F₃N₉O 
• 1172612-65-5 C₁₄H₁₃N₃ 

Relevant articles and documents

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.

1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to the use of 1 H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1 H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1 H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1 H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1 H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1 H-imidazo[4,5-c]quinolinone compounds.